$12.82
-0.09-0.70%
At close: -
$12.82
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Arcturus Therapeutics Analyst Ratings and Price Targets | NASDAQ:ARCT | Benzinga
Arcturus Therapeutics Holdings Inc has a consensus price target of $47 based on the ratings of 16 analysts. The high is $71 issued by William Blair on July 24, 2023. The low is $14 issued by Goldman Sachs on November 10, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on April 10, 2025, March 10, 2025, and March 7, 2025, respectively. With an average price target of $62.67 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 388.82% upside for Arcturus Therapeutics Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Wells Fargo
BTIG
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Arcturus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 368.02% | HC Wainwright & Co. | Ed Arce58% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2025 | Buy Now | 430.42% | Canaccord Genuity | Whitney Ijem48% | $74 → $68 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 368.02% | HC Wainwright & Co. | Ed Arce58% | $63 → $60 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 290.02% | Wells Fargo | Yanan Zhu36% | $58 → $50 | Maintains | Overweight | Get Alert |
| 02/18/2025 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2025 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 01/28/2025 | Buy Now | 219.81% | BTIG | Thomas Shrader40% | → $41 | Initiates | → Buy | Get Alert |
| 01/13/2025 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 12/16/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Reiterates | Overweight → Overweight | Get Alert |
| 11/08/2024 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 10/01/2024 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer54% | — | Reiterates | → Overweight | Get Alert |
| 08/12/2024 | Buy Now | 446.02% | Leerink Partners | Lili Nsongo7% | → $70 | Initiates | → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 391.42% | HC Wainwright & Co. | Ed Arce58% | $60 → $63 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Reiterates | → Overweight | Get Alert |
| 07/02/2024 | Buy Now | 368.02% | HC Wainwright & Co. | Ed Arce58% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 570.83% | Canaccord Genuity | Whitney Ijem48% | $87 → $86 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 368.02% | HC Wainwright & Co. | — | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | 578.63% | Canaccord Genuity | Whitney Ijem48% | $81 → $87 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 352.42% | Wells Fargo | Yanan Zhu36% | $45 → $58 | Maintains | Overweight | Get Alert |
| 03/08/2024 | Buy Now | 368.02% | HC Wainwright & Co. | Ed Arce58% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/08/2024 | Buy Now | 274.41% | Citigroup | Yigal Nochomovitz57% | $40 → $48 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem48% | — | Initiates | → Buy | Get Alert |
| 11/28/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 321.22% | Cantor Fitzgerald | Pete Stavropoulos42% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 453.82% | William Blair | Myles Minter42% | → $71 | Initiates | → Outperform | Get Alert |
| 07/14/2023 | Buy Now | — | Guggenheim | Seamus Fernandez60% | — | Maintains | Buy | Get Alert |
| 07/14/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/14/2023 | Buy Now | 321.22% | Cantor Fitzgerald | Pete Stavropoulos42% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 06/01/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Reiterates | → Buy | Get Alert |
| 05/11/2023 | Buy Now | 297.82% | HC Wainwright & Co. | Ed Arce58% | → $51 | Upgrade | Neutral → Buy | Get Alert |
| 03/29/2023 | Buy Now | 180.81% | Guggenheim | Seamus Fernandez60% | → $36 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 48.21% | HC Wainwright & Co. | Ed Arce58% | → $19 | Reiterates | → Neutral | Get Alert |
| 11/10/2022 | Buy Now | 9.2% | Goldman Sachs | Madhu Kumar72% | $8 → $14 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | 40.41% | Baird | Joel Beatty66% | → $18 | Downgrade | Neutral → Underperform | Get Alert |
| 11/03/2022 | Buy Now | — | Citigroup | Yigal Nochomovitz57% | — | Upgrade | Neutral → Buy | Get Alert |
| 11/02/2022 | Buy Now | 95.01% | Barclays | Gena Wang50% | $16 → $25 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | 243.21% | Cantor Fitzgerald | Pete Stavropoulos42% | $39 → $44 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 664.43% | Wells Fargo | Yanan Zhu36% | $105 → $98 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 24.8% | Barclays | Gena Wang50% | $17 → $16 | Maintains | Underweight | Get Alert |
| 08/10/2022 | Buy Now | — | Raymond James | Steven Seedhouse58% | — | Downgrade | Market Perform → Underperform | Get Alert |
| 07/19/2022 | Buy Now | 204.21% | Cantor Fitzgerald | Pete Stravropoulos58% | → $39 | Assumes | → Overweight | Get Alert |
| 05/24/2022 | Buy Now | -37.6% | Goldman Sachs | Madhu Kumar72% | $14 → $8 | Maintains | Sell | Get Alert |
| 05/11/2022 | Buy Now | 9.2% | Goldman Sachs | Madhu Kumar72% | $16 → $14 | Maintains | Sell | Get Alert |
| 05/11/2022 | Buy Now | 40.41% | Baird | Joel Beatty66% | $21 → $18 | Upgrade | Underperform → Neutral | Get Alert |
| 05/10/2022 | Buy Now | 32.61% | Barclays | Gena Wang50% | $21 → $17 | Maintains | Underweight | Get Alert |
| 05/10/2022 | Buy Now | 48.21% | HC Wainwright & Co. | Ed Arce58% | $25 → $19 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Arcturus Therapeutics (ARCT) stock?
The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by HC Wainwright & Co. on April 10, 2025. The analyst firm set a price target for $60.00 expecting ARCT to rise to within 12 months (a possible 368.02% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?
The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by HC Wainwright & Co., and Arcturus Therapeutics reiterated their buy rating.
When was the last upgrade for Arcturus Therapeutics (ARCT)?
The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.
When was the last downgrade for Arcturus Therapeutics (ARCT)?
The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.
When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?
While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $60.00 to $60.00. The current price Arcturus Therapeutics (ARCT) is trading at is $12.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
